BioMarin Pharmaceutical Inc. Release: American College Of Medical Genetics And Genomics Practice Guidelines Support Lifelong Therapy To Manage Phenylketonuria (PKU)
Published: Jan 13, 2014
SAN RAFAEL, Calif., Jan. 13, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that new practice guidelines issued by the American College of Medical Genetics and Genomics (ACMG) support the need for lifelong management of PHE levels in patients with phenylketonuria or PKU. The new diagnosis and management guidelines were published online in Genetics In Medicine's Advance Online Publication (AOP) service and provide the first update to recommendations for therapy of PKU since the 2001 National Institutes of Health Consensus statement.
Help employers find you! Check out all the jobs and post your resume.